Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Scout Investments Inc.

Scout Investments Inc. decreased its position in Halozyme Therapeutics, Inc. (NASDAQ:HALOFree Report) by 1.5% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 261,483 shares of the biopharmaceutical company’s stock after selling 4,095 shares during the period. Scout Investments Inc. owned about 0.20% of Halozyme Therapeutics worth $9,664,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Principal Securities Inc. acquired a new stake in shares of Halozyme Therapeutics during the 4th quarter valued at $34,000. First Horizon Advisors Inc. increased its stake in Halozyme Therapeutics by 24.5% in the fourth quarter. First Horizon Advisors Inc. now owns 1,491 shares of the biopharmaceutical company’s stock valued at $55,000 after acquiring an additional 293 shares during the period. Parkside Financial Bank & Trust bought a new stake in Halozyme Therapeutics in the fourth quarter valued at about $64,000. Headlands Technologies LLC increased its stake in Halozyme Therapeutics by 1,068.2% in the fourth quarter. Headlands Technologies LLC now owns 1,764 shares of the biopharmaceutical company’s stock valued at $65,000 after acquiring an additional 1,613 shares during the period. Finally, Quadrant Capital Group LLC increased its stake in Halozyme Therapeutics by 22.4% in the fourth quarter. Quadrant Capital Group LLC now owns 3,414 shares of the biopharmaceutical company’s stock valued at $126,000 after acquiring an additional 624 shares during the period. Institutional investors and hedge funds own 97.79% of the company’s stock.

Halozyme Therapeutics Trading Down 1.1 %

HALO traded down $0.59 during trading on Friday, reaching $50.85. 1,849,643 shares of the company’s stock were exchanged, compared to its average volume of 1,121,317. Halozyme Therapeutics, Inc. has a one year low of $32.78 and a one year high of $53.00. The company has a current ratio of 6.64, a quick ratio of 5.36 and a debt-to-equity ratio of 8.44. The stock has a market capitalization of $6.47 billion, a PE ratio of 21.01, a price-to-earnings-growth ratio of 0.58 and a beta of 1.28. The firm has a fifty day moving average price of $41.88 and a two-hundred day moving average price of $39.31.

Halozyme Therapeutics (NASDAQ:HALOGet Free Report) last posted its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported $0.71 EPS for the quarter, beating analysts’ consensus estimates of $0.64 by $0.07. Halozyme Therapeutics had a net margin of 36.94% and a return on equity of 225.71%. The company had revenue of $195.88 million for the quarter, compared to analyst estimates of $201.72 million. As a group, equities research analysts forecast that Halozyme Therapeutics, Inc. will post 3.44 earnings per share for the current fiscal year.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of the stock in a transaction dated Wednesday, May 22nd. The shares were sold at an average price of $45.38, for a total transaction of $453,800.00. Following the completion of the transaction, the senior vice president now owns 168,176 shares in the company, valued at $7,631,826.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Over the last 90 days, insiders sold 30,000 shares of company stock worth $1,255,100. 2.40% of the stock is owned by company insiders.

Analysts Set New Price Targets

HALO has been the topic of a number of analyst reports. Piper Sandler cut shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and upped their target price for the company from $48.00 to $51.00 in a research note on Friday. Wells Fargo & Company boosted their price target on shares of Halozyme Therapeutics from $48.00 to $58.00 and gave the company an “overweight” rating in a research report on Friday. HC Wainwright restated a “buy” rating and issued a $50.00 price target on shares of Halozyme Therapeutics in a research report on Tuesday. TD Cowen assumed coverage on shares of Halozyme Therapeutics in a research report on Thursday, February 29th. They issued an “outperform” rating and a $54.00 price target on the stock. Finally, JMP Securities reduced their target price on shares of Halozyme Therapeutics from $72.00 to $71.00 and set a “market outperform” rating on the stock in a research report on Wednesday, May 8th. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $54.13.

View Our Latest Stock Report on Halozyme Therapeutics

Halozyme Therapeutics Company Profile

(Free Report)

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

See Also

Institutional Ownership by Quarter for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.